U.S. market Closed. Opens in 15 hours 29 minutes

BGLC | BioNexus Gene Lab Corp. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue9.77M10.93M13.36M11.39M126.95K212.33K
Cost of Revenue8.44M9.67M11.17M9.67M71.07K183.56K
Gross Profit1.33M1.26M2.19M1.72M55.89K28.77K
Operating Expenses3.92M1.55M1.14M446.00K331.59K-31.14K
Selling, General & Admin4.41M1.73M1.20M1.33M356.64K241.93K
Research & DevelopmentN/AN/AN/AN/AN/AN/A
Other Operating Expenses-486.04K-179.28K-66.49K-886.94K-25.05K273.07K
Operating Income-2.59M-291.18K1.06M1.27M-275.70K59.90K
Other Expenses / Income-35.45K-12.48K-12.97K-11.31K25.05K273.07K
Before Tax Income-2.61M-303.66K1.04M1.26M-275.70K59.90K
Income Tax Expenses21.53K52.31K291.28K168.41K-29.24K33.45K
Net Income-2.63M-355.97K751.57K1.09M-246.47K26.45K
Interest Expenses13.93K12.48K12.97K11.31KN/AN/A
Basic Shares Outstanding15.88M14.41M14.27M8.58M7.20M5.53M
Diluted Shares Outstanding15.88M14.41M14.27M8.58M7.20M5.53M
EBITDA-2.49M-185.76K1.16M1.38M-222.37K100.51K
EBITDA Margin-25.43%-1.70%8.71%12.08%-175.16%47.34%
EBIT-2.59M-291.18K1.06M1.27M-275.70K59.90K
EBIT Margin-26.54%-2.66%7.90%11.18%-217.17%28.21%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙